BenzingaOctober 19, 2026 at 6:22 AM NY8 Days Ago
HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $140 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Cytokinetics (NASDAQ:CYTK) with a Buy and maintains $140 price target.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
